Truist Securities Maintains Buy on Biogen, Maintains $340 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas maintains a Buy rating on Biogen (NASDAQ:BIIB) with a $340 price target.
May 16, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Robyn Karnauskas maintains a Buy rating on Biogen with a $340 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $340 price target by Truist Securities suggests strong confidence in Biogen's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100